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Dry Eye Disease (DED) stems from a disruption of the homeostasis of the tear film (TF), a 
thin layer of fluid covering the ocular surface. The TF consists of numerous constituents that 
include proteins, lipids, mucins, water, electrolytes, immunoglobulins, vitamins, cytokines, and 
neuropeptides. An imbalance in any of these constituents could result in an unstable tear film, 
contributing to the pathophysiology of DED. Among these factors, neuropeptides, small 
proteinaceous substances produced and released by neurons through regulated secretory 
routes, may have a role in the pathophysiology of DED. To understand the impact of the disease 
on the concentrations of calcitonin gene-related peptide (CGRP), substance P (SP), neuropeptide 
Y (NPY) and vasoactive intestinal peptide (VIP) in the tear film, it is important to first understand 
the sample collection and quantification methods. The purpose of this thesis was to optimize a 
method to quantify the concentration of four neuropeptides using enzyme linked 
immunosorbent assay (ELISA). a common laboratory technique used to quantify the 
concentration of neuropeptides in the tear film. ELISAs have been used to determine the quantity 
of different components in blood and other bodily fluids in the human tear film. 




Chapter 3: To determine the variability of two tear collection methods, basal tear collection and 
flush tear collection, for quantifying SP, CGRP, VIP, and NPY, and to quantify the day-to-day 
variability of these neuropeptides.   
Chapter 4: To assess the validity of a commercially available ELISA kits for the quantification of 
neuropeptides. 
Chapter 5: To examine the measurement variability of two commercially available ELISA kits for 
the quantification of SP. 
Methods: 
Chapter 3: Basal and flush tears (following instillation of 20 μL of saline on the ocular surface) of 
8 healthy participants were collected from the right and left eyes respectively, using glass 
microcapillary tubes on two consecutive days. The concentrations of the four neuropeptides in 
the tears were determined using ELISA, for both collection methods, and for both days.  
Chapter 4: Basal tears (5 µL) were collected from the temporal canthus of each eye of 3 healthy 
participants using glass microcapillary tubes. To assess the validity of the ELISA kit used in Chapter 
3, two experiments were performed: a spike and recovery experiment, followed by a serial 
dilution response. In the spike and recovery experiment, 2 μL of tears from each participant were 




100 pg/mL). The concentrations of neuropeptides were quantified using ELISA and the percent 
recovery was calculated. In the serial dilution response experiment, 4 μL of tears were collected 
from a single participant and was spiked into a known concentration of NPY (100 pg/mL). Serial 
dilutions (1:2, 1:4 and 1:8) were conducted and the percent recovery was calculated. Multiple 
troubleshooting and optimizing experiments to conducted to examine the effect of using a 
blocking agent, C18 pipette tip column, protease inhibitor, and the effect of freeze storage on 
neuropeptide quantification.  
Chapter 5: SP from Phoenix Pharmaceuticals, SP from Cayman Chemicals and SP from Sigma-
Aldrich were each formulated at 0.5 mg/mL. Their UV absorbance profile from 200 nm to 300 nm 
was obtained using SoftMax Pro 5.4.1 software on a SPECTRAmax M5e ROM v2.1.35. The two SP 
from Phoenix Pharmaceuticals and SP from Sigma-Aldrich were formulated at various 
concentrations (500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.2 pg/mL, 15.6 pg/mL, to 7.8 
pg/mL and 3.9 pg/mL) and were quantified using two different ELISA kits (Phoenix 
Pharmaceuticals, Cayman Chemicals). A Bland Altman plot was used to quantify the agreement 







Chapter 3: There was no significant difference in the concentrations of CGRP, SP, NPY, and VIP 
between the two collection methods (all P > 0.19). The difference in concentrations of CGRP, SP, 
NPY, and VIP between the two study days was also not significant (P > 0.06 for all tests). 
Chapter 4: The percent recovery for spike and recovery experiment ranged between 63,953.15% 
to 13.74% for CGRP, 676.17% to 5.21% for SP and 412.42% to 7.51% for NPY. The initial 
concentration of NPY was 208 pg/mL and after the 1:2, 1:4, and 1:8 dilution, the observed 
recovery was 188.40 pg/mL for the 1:2 dilution, 153.60 pg/mL for the 1:4 dilution, and 204.28 
pg/mL for the 1:8 dilution. In the troubleshooting experiments; there were minimal differences 
in the concentration of SP associated with the use of a blocking agent; there was a reduction in 
VIP when processed using C18 column pipette tips; using protease inhibitors reduced the amount 
of VIP recovered; the amount of VIP recovered was reduced in the presence of albumin; a higher 
amount of SP was recovered in freshly collected tears compared to tears which were stored 
frozen for four months.  
Chapter 5: A similar absorbance profile was observed for SP from Phoenix Pharmaceuticals  and 
SP from sigma Aldrich. A trend toward higher variability was observed at lower concentrations of 




[-10.75, 4.01] for the Phoenix Pharmaceuticals kit, and a mean difference was -9.70%, and the 
95% limits of agreement were [-14.61, -4.79] for the Cayman Chemicals kit.  
Conclusion: 
 
Chapter 3: It was anticipated that diluting to facilitate collection using the flush tears method 
would have yielded a lower concentration than the basal tears collection method. However, the 
ELISA kits found no significant difference between the two collection methods.   
Chapter 4: High variation was observed in the recovered values of both the spike and recovery 
and the serial dilution response experiments. The troubleshooting experiments have provided 
some optimization steps to consider for tear sample collection and processing for the detection 
for neuropeptides.  
Chapter 5: The agreements of two SP standards quantified with two different SP ELISA kits were 
poor. Greater variability in fluorescence and absorbance units was associated with lower 
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Chapter 1 - Introduction  
1.1 Structure and Function of neuropeptides 
It is estimated that there are more than 100 billion neurons in the human body,1 and with it, 
hundreds of different types of neurotransmitters to transmit information from one neuron to 
another. One important class of neurotransmitters in the human body are neuropeptides. 
Neuropeptides are defined as “… small proteinaceous substances produced and released by 
neurons to communicate with each other. They are signaling molecules in the brain which are 
involved in many physiological functions.”1 Until the early 19th century, neuropeptides were 
thought to be hormones, chemical messengers that are carried from one organ to the another 
through the bloodstream.2 In the 1950s, these peptide hormones consisting of a small chain of 
amino acids were discovered in the gastrointestinal tract and later in the brain. After studying 
the biological effects of these peptide hormones, David de Wied in 1971 coined the term 
“neuropeptide”.3 Neuropeptides are secreted internally in the nervous system, where they can 
act as a neurotransmitter, or into the bloodstream as hormones.2  
Neuropeptides are signaling molecules that are released by neurons to  communicate 
with adjacent neurons and also with immune cells during inflammation.4 Neuropeptides are 
released through calcium-dependent exocytosis but are not reabsorbed into the neuron once 




breakdown by extracellular proteases.5-9 Neuropeptides are typically secreted in low 
concentrations compared to neurotransmitters and are slow-acting. The half-life of 
neuropeptides can vary depending on the region of the body. For example, the half-life of 
neuropeptides in plasma is between 2 to 7 minutes and approximately 10 to 60 minutes in 
cerebrospinal fluid.2,4,10 
1.1.1 Mechanism of Neuropeptide production 
Neuropeptides are synthesized in the soma of neurons in both the central and peripheral nervous 
system. Neuropeptides are typically 3 – 36 amino acids in size and generally have higher 
molecular weights than other neurotransmitters.1,4,5 They are derived from proteolytic cleavage 
of larger precursors, which are encoded by over 70 different genes.6,11 The precursor mRNAs are 
translated by the polyribosomes on the endoplasmic reticulum,6 and the resulting protein then 
undergoes further processing through the Golgi complex. These precursors are then packed into 
large dense core vesicles (Fig 1.1) where the proteases in the vesicles cleave the precursors into 
the final form of the neuropeptide.1,6,12 There are three different proteolytic processing steps 
that occur in the vesicle to form a mature neuropeptide. In the first step, an endopeptidase 




cleaves residues from the c terminus of a newly formed peptide. The final process involves 
converting the carboxy group at the c terminus to an amide group.6,13  
Once synthesized, these neuropeptides remain stored in large dense-core vesicles in the 
nerve axon and are released either into the bloodstream or nervous system.2,12 Once released 
into the bloodstream these neuropeptides function by binding to G-protein-coupled receptors at 
cells within their target tissues.2,1,3                      
 4 
 
Figure 2-1. Synthesis of neuropeptides in the cell soma of neurons 
from the central or peripheral nervous system
 
1.1.2 Types of neuropeptides and their function 
As previously stated, there are more than 70 genes that encode the neuropeptide precursors 
that collectively yield over 100 different types of neuropeptides.1,14 These neuropeptides are 
categorized based on gene families (e.g., opioid, vasopressin/oxytocin, Calcitonin, etc.).1,2,15,16 




With respect to the ocular surface, the neuropeptides that have attracted most attention in the 
literature are Calcitonin Gene-Related Peptide (CGRP), Substance P (SP), Neuropeptide Y (NPY), 
and Vasoactive Intestinal Peptide (VIP).4,17-22   
1.1.2.1 Calcitonin Gene-Related Peptide (CGRP) 
Calcitonin gene-related peptide is a neuropeptide that consists of 37 amino acids. It is obtained 
by alternative mRNA splicing of CAL1 gene on the 11th chromosome.15 CGRP belongs to the 
regulatory peptide or calcitonin gene family, which also includes adrenomedullin and amylin, that 
work together with CGRP as vasodilators. This neuropeptide functions by binding to two G-
protein coupled receptors, CGRP1 and CGRP2, which are extensively distributed in both the 
central and peripheral nervous systems.15 The primary function of this neuropeptide is 
vasodilation.23 For example, the relaxation of the smooth muscles in coronary arteries4 is in part 
due to the activation of the CGRP1 receptor and through the modulation of potassium 






Figure 1-2. Chemical structure of Calcitonin Gene Related Peptide 
 
1.1.2.2 Substance P (SP) 
Substance P is a neuropeptide consisting of a chain of 11 amino acids. It belongs to the tachykinin 
family, which is a group of abundantly distributed peptides in the CNS active at low 
concentrations and plays a role in gastrointestinal tract motility and secretions.16 SP functions by 
binding to the G-coupled protein receptor NK1, which ultimately regulate processes such as cell 
proliferation, neuroimmune cross-talk, and chemotaxis.16 SP is abundantly distributed in the 
limbic system located in the temporal lobe.16 This neuropeptide can act as a neurotransmitter or 




Emotional or physical stressors can modulate the tissue concentration of SP or 
immunoreactivity of SP in the amygdala (regulating fear and anxiety).16 It also plays a role in 
transmitting pain stimuli to the CNS. Additionally, in tissue injuries, SP can stimulate cell growth 
for wound healing.25,26 In the gastrointestinal tract, SP plays a role in regulating smooth muscle 
cell activity and secretion of ions and fluids from gastrointestinal epithelial cells. 27,28  
 
Figure 1-3. Chemical structure of Substance P 
1.1.2.3 Neuropeptide Y (NPY) 
Neuropeptide Y is a 36 amino acid peptide that has similarities with peptide YY and pancreatic 
polypeptide.4 This neuropeptide was discovered initially in the porcine brain in 1982.29 It is one 
of the most widely distributed peptides in the nervous system and plays a role in cell 
neurogenesis and neuroendocrine release of hormones from the hypothalamus. It is secreted 




G-protein coupled receptors Y1 and Y2, which are involved in the contraction of smooth muscles, 
and energy homeostasis.29,30  
NPY increases food appetite by decreasing the latency between meals, increasing 
motivation to eat, and by delaying satiety through increasing meal size. Additionally, it facilitates 
storage of energy as fat.31-33 It acts as a vasoconstrictor, it plays a role in secretion of growth 
hormone and insulin release, and potentially has a role in promoting obesity and diabetes.29,32,34  
 
Figure 1-4. Chemical structure of Neuropeptide Y 
1.1.2.4 Vasoactive Intestinal Peptide (VIP) 
Vasoactive Intestinal Peptide is derived from prepro-VIP, a 170 amino acid chain precursor. 




and functional similarities to gastrointestinal hormones.4 VIP functions by activating two G-
protein receptors VPAC1 and VPAC2 and facilitates smooth muscle dilation and constriction. It is 
abundant in the nervous system and in both the large and small intestines. Its function in the 
intestines is to relax smooth muscles and increase the secretion of water and electrolytes.25 It 
also regulates the circadian rhythm and has an anti-inflammatory effect by inhibiting the 
production of inflammatory cytokines and chemokines from macrophages, microglial cells, and 
dendritic cells.34-39   
 
 







1.1.3 Ocular surface neuropeptides and their functions 
Neuropeptides have a role in maintaining the immune homeostasis of the ocular surface by 
modulating both the innate and adaptive immune response on the ocular surface.4,40 The 
polymodal nociceptor nerve terminals release neuropeptides into the corneal and conjunctival 
epithelium.41 Hegarty et al. showed that 3-31% of corneal nerves express SP and 15-41% of 
corneal nerves express CGRP.42 Sensory nerve fibers releasing SP and CGRP are widely spread 
throughout the corneal stroma and epithelium.4 In contrast, NPY nerve fibers originate from 
sympathetic nerves and VIP fibers originate from parasympathetic nerves. NPY and VIP nerve 
fibers are limited to the anterior stroma and the basal epithelial cells.4 The distribution of SP and 
CGRP nerve fibers are equally abundant in the stroma and the distribution of SP is fewer than 
CGRP in the epithelium.4 A study by Muller et al showed that 60% of the polymodal nociceptor 
sensory nerve endings release CGRP, 20% release SP, and the remaining 20% release NPY and 
VIP.43  As there is not enough evidence on the parasympathetic innervation to the human 
cornea,44 the release of VIP from parasympathetic nerve fibers is relatively unknown.   
Recent studies show that both SP and CGRP promote corneal wound healing.4,19 SP 
restores corneal sensitivity and promotes wound healing in diabetes.4,34 VIP is involved in 




of mucin from conjunctival goblet cells.45 The precise role of NPY is still ill-defined, but may play 
a role in cell proliferation and neurogenesis.4 
1.1.4 Mechanism of neuropeptide production during inflammation 
Several studies have shown that neuropeptides are involved in the processing of noxious 
stimuli.1,2,4,34,46,47 When nociceptors from nerve endings are stimulated, a signal is transmitted 
through the spinal cord and to the brain through neural pathways. The terminus of sensory 
nerves releases CGRP and SP and activates the innate immune system (e.g., mast cells, basophil, 
neutrophil, macrophages) and adaptive immune cells (e.g., T lymphocytes, B lymphocytes).4 The 
immediate response is vasodilation and increased vascular permeability.48 When the 
inflammation terminates the neutrophils undergo programmed cell death and are engulfed by 
macrophages and the anti-inflammatory process starts.49  
 On the ocular surface the cornea and conjunctiva contain sensory nerves that are divided 
into mechanoreceptors (low threshold), mechano-nociceptors (high threshold), polymodal 
nociceptors, and cold receptors.50 About 70% of the nerves are polymodal nociceptors that are 
stimulated by mechanical force, chemical irritants, inflammatory cells, and from plasma leakage 
from the blood vessels.50,51 Approximately 20% of sensory nerves contain mechanoreceptors and 




the remainder 10 – 15% have cold receptors. The polymodal nociceptor nerve terminals releases 
neuropeptides into the corneal and conjunctival epithelium.50,52   
 These polymodal nociceptors conduct impulses in an antidromic direction in which the 
impulses are conducted from the axon terminal to the cell soma resulting in synthesis and release 
of neuropeptides from nerve endings.52 This antidromic stimulation occurs due to tissue injury 
or inflammation that releases inflammatory mediators. These inflammatory mediators change 
the electrical activity of the nerve resulting in release of neuropeptides.50 These neuropeptides 
facilitate vasodilation, vascular permeability, cytokine release, and release of innate and adaptive 
immune cells.50,53,54 The excited nerve endings stimulate the non-injured branches of the axon to 
release neuropeptides. 55 
1.2 Methods for quantifying neuropeptides in the tear film  
In the reported literature, several methods have been described detailing the collection and 
quantification of neuropeptides from the tear film.17,18,20,21,56 The collection of basal tears57,58 
could be facilitated from the temporal canthus using glass capillary tubes.20,21 Other methods 
include placing a micro-sponge at the inferior conjunctival fornix to soak up tears19 or the use of 




Collecting basal tears from patients with dry eye disease (DED) is difficult as there are 
minimal amounts of tears on the ocular surface. This difficulty is compounded by the rapid 
evaporative loss of tears.58 To overcome this difficulty, Bjerrum and Prause introduced the “eye-
flush” tear collection method, where a fixed volume of sterile saline is instilled onto the ocular 
surface and the effluent is collected using a microcapillary tube.59 This tear collection method has 
been used to reduce tear collection time and collect a significantly higher volume of sample. 
While adding saline  would dilute the tear film constituents, Markoulli et al. showed that relative 
protein concentrations remain the same between basal and flush tears.56 
The most common method for quantifying neuropeptides in the tear film is through an 
enzyme-linked immunosorbent (ELISA) assay.17-22,56,60 An ELISA assay is a plate-based technique 
where an antibody is coated to the bottom of the plate. A sample is added, and the analyte being 
quantified binds with the antibody attached to the plate. Next, a second antibody carrying an 
absorbent dye or fluorescent molecule is added and binds to the analyte. An enzyme conjugate 
is then added to each well to amplify the signal. Following this, a substrate solution is added to 
react with the enzyme conjugate and the fluorescence or absorbance is measured. 
Other methods for detecting and quantifying neuropeptides include mass spectrometry 
(MS)18 and high performance liquid chromatography (HPLC).17 Mass spectrometry is an analytical 




These ions are separated based on their unique mass to charge ratio and are presented as a mass 
spectrum. An advantage of this technique is that it is highly sensitive and only requires a small 
amount of sample volume.61 For quantifying neuropeptides, MS identifies neuropeptides based 
on reference values in MS fragmentation databases.62 HPLC uses a high pressure pump to drive 
the sample through a column that separates the components to identify, quantify, or purify the 
individual components. A chromatogram is generated to identify the eluted peptide from the 
column.63 
1.3 Neuropeptides in Contact Lens (CL) wear  
There are over 140 million contact lens (CL) wearers worldwide, of which up to 51% discontinue 
wear due to discomfort.64 The reason behind the discomfort is multifactorial, one of which may 
be due to inflammation.51 The mechanical interaction of the lens on the ocular surface could 
stimulate nociceptors in the cornea and lids. The bacterial adherence, presence of denatured 
proteins, and use of lens care solutions may induce corneal or conjunctival toxicity, or papillary 
conjunctivitis.65,66 These conditions can lead to the release of inflammatory mediators.51    
Neuropeptides are important neurotransmitters on the ocular surface and may have a 
role in CL-related discomfort.21 Substance P may induce neurogenic inflammation in the cornea 




by Golebiowski et al. showed that there was no significant difference in concentration of 
neuropeptides between contact lens wearers and non-lens wearers, however this may be due to 
the small sample size of the study.21 Additional studies on the role of neuropeptides in CL 
discomfort could potentially be valuable to elucidating the mechanisms behind discomfort and 
CL discontinuation.   
1.4 Neuropeptides in Dry Eye Disease (DED) 
The Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) definition of dry 
eye disease (DED) is “… a multifactorial disease  of the ocular surface which is characterized by a 
loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film 
instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory 
abnormalities play etiological roles.”67 There are more than 344 million people worldwide who 
suffer from DED.68,69 Studies have shown that there are alterations in nerve morphology in 
patients with DED and a decrease in the production of neurotransmitters.60,70,71 In aqueous 
deficient dry eye, as seen in Sjögren’s syndrome, there is a decrease in tear production due to 
inflammation of the lacrimal gland.60 Decreased tear production stimulates the ocular surface 
nerve endings and gives rise to symptoms of dryness and burning. This results in the release of 




very few studies examining the relationship between DED and neuropeptides.4 A study by 
Lambiase et al. showed a significant decrease in the concentrations of CGRP and VIP in patients 
with dry eye when compared with healthy individuals, but no significant decrease in 
concentrations of SP and NPY in patients with dry eye when compared with healthy individuals. 
The reduction may be attributed to impaired lacrimal function.60 There is a need to better 
understand the mechanism and role of neuropeptides in DED.  
Table 3-1. Summarsing the mean results, tear collection method, analytical method and type of 
participants recruited in the literature.  




Neuropeptide  Mean results  
Fujishima et al.22  a) Allergic 
conjunctivitis 








Micropipette ELISA SP SP - 70.9 pg/mL  
 
 
Varnell et al.18 a) Healthy 
normals 
 





Yamada et al17 a) Healthy 
normals 
 
Micropipette ELISA SP SP - 306.0 pg/mL 
 





Dry sharp tip 
microsponge 
ELISA SP, CGRP, 
NPY, VIP 
SP - 2.1 ng/mL 
CGRP - 5.3 ng/mL 
NPY - 3.1 ng/mL 
VIP - 4.1 ng/mL 
Sacchetti et al.19 b) Healthy 
normals 
 
Dry sharp tip 
microsponge 
ELISA SP, CGRP, 
NPY, VIP 
SP - 3.4 ng/mL 
CGRP - 6.7 ng/mL 
NPY - 3.5 ng/mL 
VIP - 5.0 ng/mL 
 
 
Lambiase et al60 a) Sjögren 
syndrome DED 
Dry sharp tip 
microsponge 
ELISA CGRP, NPY CGRP - 6.0 ng/mL 
 NPY - 1.5 ng/mL 
 
Lambiase et al60 b)Non-Sjögren 
syndrome DED 
Dry sharp tip 
microsponge 
ELISA CGRP, NPY 
 
CGRP -3.0 ng/mL 









CGRP - 2.3 ng/mL 









Dry sharp tip 
microsponge 




CGRP - 6.0 ng/mL 
 NPY - 4.3 ng/mL 
 SP - 2.3 ng/mL 
 VIP - 4.5 ng/mL 
e) Dry eye 
disease 
 
Dry sharp tip 
microsponge 
ELISA SP, CGRP, 
NPY, VIP 
 
CGRP - 3.6 ng/mL 
 NPY - 3.1 ng/mL 
 SP - 2.6 ng/mL 
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Chapter 2 – Thesis Rationale  
The role of neuropeptides and their role in the inflammatory process has been studied 
extensively.2 However, the focus on the role of neuropeptides in ocular surface disease related 
to both dry eye and contact lens wear has only come to light recently.4,17-22,60 Most of the studies 
are focused specifically on either SP or CGRP, but few studies that discuss the function or the 
concentration of all  neuropeptides in the tear film.19,60  
The general role of neuropeptides in the human body is in maintaining metabolism, food 
intake and inflammation.25,27,34,46 There is a need to understand the role of these neuropeptides 
on the ocular surface, how they function, and their relationship to inflammatory ocular surface 
diseases. Studies have shown that the concentrations of SP and CGRP decrease during severe 
DED and increase in allergic conditions, but there is minimal information on the alteration of the 
level of VIP and NPY during other ocular surface diseases or inflammation.60  
There is large variation in the concentration of neuropeptides in the tear film as reported 
in the literature. For example, Lambiase et al. showed that the concentrations of CGRP in the tear 
film of healthy humans was between 2.5 ng/mL and 10.5 ng/mL,60 whereas a study by 
Golebiowski et al. reported the concentrations of CGRP to be between 1.98 ng/mL and 75.03 




were both determined using commercially-available ELISA kits. It was not known whether this 
variability was due to natural physiological variability, the tear collection method, or the 
technique used to quantify the concentration of the neuropeptides. In order to determine the 
source of this variability, there is a need to accurately and precisely measure the concentration 
of neuropeptides in the tear film. This shifts the focus to examining the techniques for 
neuropeptide quantification. Moreover, there has been no studies evaluating the validity of the 
ELISA kits for the measurement of neuropeptides. This thesis focused on the quantification and 
validation of neuropeptide ELISA kits. In order to build on the current work in the literature, this 
thesis focused on four neuropeptides that were commonly studied in the tear film CGRP, SP, NPY, 








Chapter 3 – Method optimization to measure the level of four 
neuropeptides in the human tear film 
3.1 Introduction 
There are several methods described for tear collection and for measuring the concentration of 
neuropeptides in the tear film.17,19-22,56,60 The amount of SP and CGRP have been previously 
studied,17,18,20,21 but the concentration of NPY and VIP in the tear film is still relatively unknown. 
A study by Sacchetti et al. showed an increase in concentration of all four neuropeptides (SP, 
GCRP, VIP, NPY) in subjects with allergic conjunctivitis compared to healthy individuals.19 A study 
by Lambiase et al. showed that the concentration of these neuropeptides decreased in DED.60  
There is large variation in the concentration of neuropeptides reported in the 
literature21,60, and it remains unclear if these differences are true patient differences, or whether 
they may be due to differences in the tear collection technique, or the ELISA kit used for 
quantification.21,60 To highlight this, Markoulli et al. showed no significant difference in 
concentration of tear film SP when the tears were collected with either a 20 μL or a 60 μL saline 
flush, where the 3-fold dilution of the tear film was expected to significantly dilute the 




The purpose of this study was to replicate the work of Markoulli et al and determine the 
variability between basal and flush tears for not only SP, but also for CGRP, VIP, and NPY. 
Additionally, the study aimed to quantify the day-to-day variability of the four neuropeptides.   
3.2 Methods  
This was a prospective cross-sectional study that enrolled a total of 10 healthy 
asymptomatic, non-CL wearers between 18 and 40 years of age. This study received ethics 
approval by the Office of Research Ethics at the University of Waterloo prior to participant 
enrollment.  
All participants completed the Ocular Surface Disease Index (OSDI) questionnaire,72 and 
those with an OSDI score of greater than 12 were excluded. For basal tear collection, participants 
were asked to blink three times and 5 μL of tears were collected from the temporal canthus of 
the right eye using a 10 μL glass capillary tube (Wiertrol II, Thermo Fisher Scientific, Ottawa, ON, 
CA). For flush tear collection, 20 μL of sterile saline were instilled into the left eye and 5 μL of 
tears were collected from the temporal canthus using a 10 μL glass capillary tube. The collected 
tears were immediately transferred to a microtube (Thermo Fisher Scientific, Ottawa, ON, CA) 
and stored at -80°C. The participants were asked to return the following day and tears were 




    
Figure 3-1. Tear collection from the temporal          Figure 3-2. Tears transferred to microtube 
canthus of the left eye using glass capillary tube                          from glass capillary tube  
                                                                                                      
3.2.1 Neuropeptides Quantification 
The concentrations of each neuropeptide were determined using ELISA kits specific for each 
neuropeptide (CGRP, SP, NPY, VIP) (Phoenix Pharmaceuticals, Burlingame, CA, USA). Standards 
were prepared in accordance with the manufacturer instructions (Fig 3-3).73 The plates were pre-
coated with the capture antibody. 50 μL of prepared tear samples were added in duplicates at a 
1:50 dilution. Then, 25 μL of the antibody-enzyme conjugate was added to each well and the 
plate was then incubated for 24 hours at 4°C. Excess reagent was removed by washing the plate 
three times with buffer and the substrate solution was added. After 20 minutes of incubation, 
the reaction was stopped and the fluorescence of each well was read at 325 nm for excitation 
and 420 nm for emission using SoftMax Pro 5.4.1 on SPECTRAmax M5e ROM v2.1.35 (Molecular 




                 
Figure 3-3. Neuropeptide ELISA Procedure (Image obtained from Neuropeptide ELISA kit 




3.2.2  Statistical Analysis  
Statistical analysis was conducted using GraphPad Prism 8.3.0. (San Diego, CA, USA). Shapiro-Wilk 
normality test was used to test data the distribution of the data for normality. Unpaired t-test 
was used to test the difference in the concentration of each of the four neuropeptides between 
basal and flush tears, and between the concentrations on day 1 and day 2. A P-value of < 0.05 
was considered statistically significant.                                              
3.3 Results   
A total of 8 participants (2 males and 6 females) completed the study, with the mean age of 28 ± 
5 years. Two participants were excluded from the study due to OSDI scores of 18.75 and 14.58. 
The average OSDI score was 4.92 ± 2.32.   
There was no significant difference in the concentrations of CGRP, SP, NPY, and VIP 
collected with either basal or flush tears (all P > 0.19) and no significant difference in the 
concentration of each of the neuropeptides between day 1 and day 2 (all P > 0.06). 
3.3.1 Calcitonin Gene Related Peptide (CGRP) 
The concentration of CGRP from basal tears was 2.88 ± 1.18 ng/mL on day 1 and 3.32 ± 1.18 




4). The amount of CGRP in flush tears was 3.21 ± 1.39 ng/mL on day 1 and 2.28 ± 1.37 ng/mL on 
day 2. The difference was not statistically significant (P = 0.19). There was no significant 
difference in CGRP concentrations between basal and flush tears for both day 1 (P = 0.61) and 
day 2 (P = 0.12). Fig 3-5 shows individual participant data for basal and flush tears between day 
1 and day 2.  
 






Figure 3-5. Change in CGRP concentration for each participant on day 1 and day 2 for    
basal/flush tear collection 
 
3.3.2 Substance P (SP) 
The concentration of SP in basal tears was found to be 2.61 ± 0.93 ng/mL on day 1 and 2.70 ± 
1.04 ng/mL on day 2. The difference in concentration was not statistically significant (P = 0.86) 
(Fig 3-6). The amount of SP in flush tears was found to be 1.76 ± 0.72 ng/mL on day 1 and 2.34 ± 
0.95 ng/mL on day 2. This difference was not statistically significant (P = 0.19). There was no 
significant difference in SP concentrations between basal and flush tears for day 1 (P = 0.06) and 
day 2 (P = 0.47). Fig 3-7 shows individual participant data for basal and flush tears between day 










Figure 3-7. Change in SP concentration for each participant on day 1 and day 2 for basal/flush 
tears collection 
 
3.3.3 Neuropeptide Y (NPY) 
The concentration of NPY in basal tears was found to be 1.91 ± 0.84 ng/mL on day 1 and 2.01 ± 
0.76 ng/mL on day 2. The difference in concentration was not statistically significant (P = 0.81) 
(Fig 3-8). The amount of NPY in flush tears was found to be 1.66 ± 0.72 ng/mL on day 1 and 1.38 
± 0.62 ng/mL on day 2. The difference was not statistically significant (P = 0.42). There was no 




day 2 (P = 0.09). Fig 3-9 represent individual participant data for basal and flush tears between 
day 1 and day 2.  
 





       Figure 3-9. Change in VIP concentration for each participant on day 1 and day 2 for basal/flush 
tears collection 
 
3.3.4 Vasoactive intestinal peptide (VIP)  
The concentration of VIP in basal tears was found to be 3.05 ± 0.85 ng/mL on day 1 and 3.03 ± 
0.80 ng/mL on day 2. The difference in concentration was not statistically significant (P = 0.97) 
(Fig 3-10). The amount of VIP in flush tears was found to be 2.77 ± 1.53 ng/mL on day 1 and 2.60 
± 1.04 ng/mL on day 2. This difference was not statistically significant (P = 0.82). There was also 




and day 2 (P = 0.44). Fig 3-11 shows the individual participant data for basal and flush tears 
between day 1 and day 2.  
 





Figure 3-11. Change in VIP concentration for each participant on day 1 and day 2 










3.4 Discussion and conclusion 
This study found no significant difference in the concentrations of CGRP, SP, NPY and VIP using 
two different tear collection methods, and no significant difference in the concentrations of 
neuropeptides between two consecutive days.  
This study reflects the findings in Markoulli et al, where they also observed no significant 
difference in the concentrations of SP between basal tear and flush tear collection, using both 20 
µL and 60 µL of saline.20 Similarly, in this study, no significant difference was observed between 
basal and flush tears (20 µL) for all four neuropeptides. Using flush tears for collection was 
previously shown to significantly dilute protein concentrations within collected tears, however 
the relative protein concentrations were comparable to that of basal tears.56 Given that no 
reductions were observed in neuropeptide concentration for Markoulli et al and in this study,20 
a possible explanation is that the ELISA assays may not be optimal for tear film samples. Another 
factor to consider is that a sample size of only 8 participants in this study may have been too low 
to detect a difference. To rule out the former, further work to elicit the nature and quality of the 






Chapter 4– Method Optimization  
4.1 Introduction 
The ELISA is a commonly used laboratory technique to determine the quantity of different 
components in blood and other bodily fluids. Recent studies have used this technique for the 
quantification of neuropeptides in the tear film.17-22 To determine if these ELISA kits are internally 
valid in the quantification of neuropeptides in bodily fluids, there are two types of tests that could 
be used. In one of the tests, a known amount of analyte is added (spiked) to the sample that is 
being tested. Then, an ELISA is conducted to quantify the spiked sample (recovery) to determine 
how close the observed value is from the expected. The second test to determine the internal 
validity is through conducting a serial dilution of a known analyte. In this method, a sample of 
known concentration is serially diluted, and the response (which should reflect the dilution 
factor), is measured. The observed and expected values from these tests should be within 80-
120% of each other.74 The findings in the previous chapter, where no significant difference in 
concentrations between basal and flush tears were detected, has raised questions about the 
validity of the ELISA kits used. The purpose of this chapter was focused on eliciting information 





A total of 3 healthy non-CL wearers (2 males, 1 female) with mean age of 28.6 ± 1.6 were enrolled 
in this study. This study received ethics approval by the Office of Research Ethics at the University 
of Waterloo prior to participant enrollment.  
Participants were asked to blink three times and 5 μL of basal tears were collected from 
the temporal canthus of each eye, using a 10 μL glass microcapillary tube (Wiertrol II, Thermo 
Fisher Scientific, Ottawa, ON, CA). The collected tears were pooled and immediately transferred 
to a microtube (Thermo Fisher Scientific, Ottawa, ON, CA) and stored at -80°C. This was repeated 
the following day. 
4.2.1 Spike and Recovery  
The standards from ELISA kits for quantifying CGRP, SP, and NPY (Phoenix Pharmaceuticals, 
Burlingame, CA, USA) were formulated into three different concentrations: 100 pg/mL, 10 pg/mL, 
and 1 pg/mL. A volume of 108 µL of each neuropeptide concentration was added (spiked) to 
three different collected tear samples (2 µL) from each participant. Non-spiked tear samples were 
used as control. The three spiked samples for each concentration and unspiked samples were 
added to the ELISA plate and incubated for 15 minutes. Then, 25 μL of the antibody-enzyme 




reagent was removed by washing the plate three times with buffer. The substrate solution was 
then added to each well. After 20 minutes of incubation, the reaction was stopped and the 
fluorescence of each well was read at 325 nm for excitation and 420 nm for emission using 
SoftMax Pro 5.4.1 on SPECTRAmax M5e ROM v2.1.35 (Molecular Devices, San Jose, CA 95134, 
USA). The percent recovery of the spiked sample was calculated using the following equation: 
 
                                                       
4.2.2 Serial Dilution Response 
For this experiment 5 μL basal tear were collected from both eyes from a single healthy non-CL 
wearer (same participant from the previous experiment) using a 10 μL glass microcapillary tube 
(Wiertrol II, Thermo Fisher Scientific, Ottawa, ON, CA). The collected tears were immediately 
transferred to a microtube (Thermo Fisher Scientific, Ottawa, ON, CA) and stored at -80°C. Only 
neuropeptide NPY was quantified. The NPY concentrations in the tears were determined using 




accordance with the manufacturer instructions.73 A concentration of 100 pg/mL NPY was used to 
spike 4 μL of tear sample. After spiking the spiked sample was diluted in 205 µL of buffer.    
a) 11 μL of 100 pg/mL NPY was added to 4 μL of the tear sample. The spiked sample was 
then diluted in 205 µL of buffer. 
b) 110 μL from previous dilution was diluted in 110 μL of buffer to obtain a 1:2 dilution 
c) 110 μL from 1:2 dilution was again diluted in 110 μL of buffer to obtain a 1:4 dilution 
d) 110 μL from 1:4 dilution was again diluted in 110 μL of buffer to obtain a 1:8 dilution 
  All the diluted samples were added to the plate in duplicates. Then, 25 μL of the antibody-
enzyme conjugate was added to each well and the plate was then incubated for 24 hours at 4°C. 
Excess reagent was removed by washing the plate three times with buffer and a substrate 
solution was added. After 20 minutes of incubation, the reaction was stopped and the 
fluorescence of each well was read at 325 nm for excitation and 420 nm for emission using 
SoftMax Pro 5.4.1 on SPECTRAmax M5e ROM v2.1.35 (Molecular Devices, San Jose, CA 95134, 
USA). The percentage difference between observed and expected values were calculated using 





4.3 Results  
4.3.1 Recovery of neuropeptides 
The results (Tables 4-1, 4-2, 4-3) show the percent recovery of the spiked samples for 
neuropeptides CGRP, SP, NPY. These results were calculated using the % recovery equation 
described above. The neuropeptide concentrations in unspiked tear samples were deducted 
from the spiked samples. Although the recovery was within 80-120% of the expected values, 
there were a considerable number of samples that were greater than or less than this range.   
Table 4-1. Spike and recovery of CGRP in tear film samples 







1 1 pg/mL 0.982 pg/mL 8.38 pg/mL 853.36 
10 pg/mL 9.82 pg/mL 1.94 pg/mL 19.75 
100 pg/mL 98.2 pg/mL Not measureable Not measureable 
2 1 pg/mL 0.982 pg/mL 628.02 pg/mL 63,953.15 
10 pg/mL 9.82 pg/mL 1.35 pg/mL 13.74 
100 pg/mL 98.2 pg/mL Not measureable Not measureable 




10 pg/mL 9.82 pg/mL 10.48 pg/mL 106.72 
100 pg/mL 98.2 pg/mL Not measureable Not measureable 
 
Table 4-2. Spike and recovery of SP in tear film samples 







1 1 pg/mL 0.982 pg/mL 6.64 g/mL 676.17 
10 pg/mL 9.82 pg/mL 1.29 pg/mL 13.13 
100 pg/mL 98.2 pg/mL 5.12 pg/mL 5.21 
2 1 pg/mL 0.982 pg/mL 4.37 pg/mL 445.01 
10 pg/mL 9.82 pg/mL 1.39 pg/mL 14.15 
100 pg/mL 98.2 pg/mL Not measureable Not measureable 
3 1 pg/mL 0.982 pg/mL Not measureable Not measureable 
10 pg/mL 9.82 pg/mL 5.27 pg/mL 53.66 








Table 4-3. Spike and recovery of NPY in tear film samples 







1 1 pg/mL 0.982 pg/mL 0.76 pg/mL 77.39 
10 pg/mL 9.82 pg/mL 1.10 pg/mL 11.20 
100 pg/mL 98.2 pg/mL 22.9 pg/mL 23.31 
2 1 pg/mL 0.982 pg/mL 4.05 pg/mL 412.42 
10 pg/mL 9.82 pg/mL 1.89 pg/mL 19.24 
100 pg/mL 98.2 pg/mL 7.38 pg/mL 7.51 
3 1 pg/mL 0.982 pg/mL 3.48 pg/mL 354.37 
10 pg/mL 9.82 pg/mL 2.21 pg/mL 22.50 







4.3.2 Dilution response 
The initial concentration of NPY was 208.00 pg/mL. For the dilutions; 1:2 yielded 188.40 pg/mL, 
1:4 yielded 153.60 pg/mL, and 1:8 yielded 204.28 pg/mL. The percentage of expected recovery 
for 1:2 was 181%, 1:4 was 295% and the difference for 1:8 was 785%.  
Table 4-4. % recovery of NPY in tear film sample dilutions 
        
Dilutions 
 


















1:8 26.00 pg/mL 
 
204.28 pg/mL 785 
 
4.4 Supplemental Troubleshooting Experiments  
Both the spike and recovery and serial dilution response experiments yielded results which were 
unexpected, bringing into question the validity of the ELISA kits. This also suggested the 
possibility that other components in the tear film were interfering with the assay. To determine 




further evaluate validity and the nature of the assay, the following experiments were conducted, 
and their summaries are described below.    
4.4.1 Use of a blocking agent  
The tear film have many components such as lipids, proteins, and mucins, 75 in addition to the 
analyte of interest. Therefore, there is a possibility that some of these extraneous components 
can interact with the antibodies and confound results. In the previous study, the results of the 
spike and recovery and serial dilution response experiments suggested the possibility of 
interference occurring within the ELISA assay. One possibility is the presence of non-specific 
binding and interference with antibody binding. To minimize this interference, a blocking agent 
was used reduce non-specific binding in the ELISA plate.  
Purpose: To determine the effect of a blocking agent on neuropeptide quantification. 
Method:  Block ACE (Bio-Rad laboratory, Mississauga, Canada) was used to block non-specific 
binding sites of an SP ELISA plate (Phoenix Pharmaceuticals, Burlingame, CA, USA). Block ACE was 
dissolved in water and two concentrations of Block ACE were formulated: 0.4 g/mL and 0.1 g/mL. 
The Block ACE was then added to specified wells of an SP ELISA plate 30 minutes prior to 
conducting the assay. After 30 minutes, the contents of the wells were discarded and the ELISA 




pg/mL prepared by diluting SP in assay buffer. Quantification of the two SP control 
concentrations without Block ACE was conducted as a control. The concentrations of SP 
associated with 0.4 g/mL, 0.1 g/mL no blocking, was compared.  
Results: For the 1000 pg/mL control concentration of SP, the amount recovered from the well 
incubated with 0.1 g/mL Block ACE was 1018.21 pg/mL. The amount of SP recovered from 0.4 
g/mL Block ACE was 981.78 pg/mL. The amount recovered from the blank well was 1039.73 
pg/mL (Fig 4-1). For the 100 pg/mL control concentration of SP, the recovered concentration at 
0.1 g/mL Block ACE was 21.18 pg/mL SP and 178.81 pg/mL SP for 0.4 g/mL Block ACE. The amount 





Figure 4-1. Amount of SP recovered from using 0.4 g/mL and 0.1 g/mL Block ACE. 
 
Conclusion: The results suggest that using a blocking agent does not have any influence on the 






4.4.2 C18 column tips  
The tear film contains a large amount of proteins75 and it is possible that protein were interfering 
with the ELISA assay. To reduce the amount of protein in the tear samples prior to conducting an 
ELISA assay, passing tear samples through a C18 column may be helpful. A C18 column consists 
of silica particles with carbon chains attached. When the sample is passed through the column 
the carbon chains strongly retain non-polar solutes and the polar solutes are eluted 
Purpose: The purpose of this experiment was to pre-separate other components in the tear film 
using C18 column tips (as per manufacturer instructions) and determine if pre-separation 
influences VIP quantification.  
Method: A total of 50 µL of basal tears were collected using glass capillary tubes and pooled from 
both eyes of 5 healthy participants (3 females, 2 males) with mean age of 29.4 ± 2.8. C18 pipette 
tips (Thermo Fischer Scientific, Mississauga, ON, CA) were used to process the tears. First, 10 µL 
of tears were diluted with 10 µL of Buffer A provided with the VIP ELISA kit (Phoenix 
Pharmaceuticals, Burlingame, CA, USA). Then 10 µL C18 pipette tips were prewashed using 50 µL 
of buffer A, followed by 150 µL of Buffer B of the ELISA kit. 10 µL of the tear sample was loaded 
into the tip and slowly washed with 150 µL of Buffer A and discarded. Then the peptide was 
eluted slowly with 150 µL Buffer B into a microtube. The eluent was dried and stored at -20°C 




Known concentrations of VIP 1000 pg/mL and 100 pg/mL were prepared by diluting VIP 
in assay buffer and passed through the C18 pipette tips as described earlier. The eluent was dried 
and stored at -20°C. An ELISA was performed to quantify the amount of VIP within the eluents. A 
separate set of 1000 pg/mL and 100 pg/mL of VIP were formulated but were not passed through 
the C18 pipette tips and were used as control.  
Results: The VIP concentration from the tear eluent was beyond the lower range of detection of 
the ELISA kit. Overall, a reduction was observed for the concentrations of VIP that were passed 
through the C18 pipette tip. For the 1000 pg/mL VIP, the amount recovered after using the C18 
pipette tip was 265.28 pg/mL, and 1048.39 pg/mL was recovered from not using the C18 pipette 
tip (Fig 4-2). For the 100 pg/mL VIP concentration, the amount recovered from passing through 
the C18 pipette was beyond the lower range of detection of the kit, whereas not using the C18 





Figure 4-2. Difference between processed and unprocessed VIP samples of 1000 pg/mL and  
100 pg/mL concentrations through C18 column tips 
 
Conclusion: The results suggest that C18 pipette tips reduced VIP concentrations and that C18 






4.4.3 Interference of Albumin 
One protein found in high concentrations in the tear film is albumin.76 It is possible that albumin 
may interact with the ELISA assay quantification.  
Purpose: To evaluate the effect of albumin on ELISA assay performance.  
Method: Three solutions of VIP (1000 pg/mL, 100 pg/mL, and 10 pg/mL) were prepared by serially 
diluting 100,000 pg/mL VIP in bovine serum albumin solution (Sigma-Aldrich, Oakville, ON, 
Canada). The bovine serum albumin solution was prepared by mixing 1 mg bovine serum albumin 
in 1 mL of MilliQ water. Another three solutions of VIP (1000 pg/mL, 100 pg/mL, and 10 pg/mL) 
were prepared in buffer as a control. The concentrations of VIP were determined using an ELISA 
kit as previously described, as per manufacturer instructions.  
Results: Only data for 1000 pg/mL of VIP with and without albumin was available. VIP 
concentration associated with albumin was 535.06 pg/mL, and VIP without albumin was 939.72 
pg/mL (Fig 4-3). The other two experimental conditions 100 pg/mL and 10 pg/mL VIP yielded 





Figure 4-3. Comparison between 1000 pg/mL of VIP diluted in albumin and  
1000 pg/mL of VIP diluted in diluent buffer. 
 






4.4.4 Using Protease Inhibitors and Fresh tears  
A potential reason for reduced neuropeptide concentrations may be due to freeze storage and 
degradation of tear samples over time. The half-life of neuropeptides is no more than 10 
minutes10 and there may already be neuropeptides lost by the time the samples arrive at the 
freezer. Another possible cause for degradation can be freeze-thaw cycles. Further, proteases 
and peptidases in the tear film may also contribute a role in reducing the concentration of 
neuropeptides.  
Purpose: The purpose of this experiment was to test the effect of freeze storage on neuropeptide 
concentrations, and to test the effect of a protease inhibitor on SP quantification.  
Methods: Protease inhibitor (Thermo Fisher Scientific, Ottawa, Canada) was prepared by 
dissolving 10 g of protease inhibitor into 100 mL of buffer. 10 µL of basal tears were collected 
from each eye and pooled to obtain a total of 20 µL from a single healthy participant using a glass 
microcapillary tube as previously described. 10 µL of tears were diluted in the protease inhibitor 
buffer within 10 minutes of collection. The remaining 10 µL of tears were diluted in assay buffer. 
Both diluted tear samples were each divided in 2 µL and 4 µL aliquots. A four-month old tear 
sample stored at -80°C from the same participant was retrieved and was aliquoted and treated 




tear samples into 2 µL and 4 µL was to test if 4 µL of tears yield double the amount of SP as the 
2 µL aliquot. In addition, 1000 pg/mL and 10 pg/mL of SP were also prepared with and without 
the protease inhibitor to test the effect of the protease inhibitor on pure SP. The SP ELISA was 
conducted as previously described. 
Results: The 2 µL of freshly collected tears diluted in protease inhibitor showed a concentration 
of 1.15 pg/mL (Fig 4-4), while the 2 µL of freshly collected tears diluted in assay buffer showed a 
concentration of 2.50 pg/mL (Fig 4-4). 4 µL of freshly collected tears diluted in assay buffer 
yielded double (4.20 pg/mL) the amount of SP as in 2 µL tears (Fig 4-4). Similarly, 2 µL of frozen 
tears diluted in protease inhibitor showed a concentration of 0.65 pg/mL and 2 µL of frozen tears 
diluted in assay buffer showed a concentration of 1.20 pg/mL (Fig 4-5). 
 There was a decrease in concentration of SP tears which were frozen compared to that 
which were freshly collected. 2 µL of freshly collected tears diluted in assay buffer showed a 
concentration of 2.50 pg/mL (Fig 4-4), and tears which were frozen showed a concentration of 
1.20 pg/mL (Fig 4-5).  
The amount recovered from 1000 pg/mL SP diluted in protease inhibitor was 753.99 




pg/mL SP diluted in protease inhibitor was 9.17 pg/mL, and without protease inhibitor was 10.85 
pg/mL (Fig 4-6).  
 





                         
Figure 4-5. Effect of protease inhibitors on the concentration of SP in tears stored at -80°C.  





Figure 4-6. Effect of protease inhibitors on the 1000 pg/mL and 10 pg/mL SP.  
 
 Conclusion: Tears stored at -80°C yielded a lower concentration of SP compared to freshly 
collected tears and the effect appeared to be independent of volume. Adding protease inhibitors 







4.5 Discussion and Conclusion  
The focus of this chapter was to elicit further information on the validity of the ELISA kits. The 
spike and recovery and serial dilution response experiments supplied highly variable results. 
Some possible reasons for this may be due to non-specific binding on the ELISA plate, 
interference from tear film proteins and protease, and sample storage conditions. After 
subsequent experimentation with adding blocking agents, employing C18 separation, testing the 
interference of albumin, the use of protease inhibitors, and testing at different storage 
conditions, it was determined that freshly collected tears were associated with the greatest 
recovery in neuropeptide concentration. It was also determined that blocking agents did not 
appear to impact the quantification, that albumin may reduce the amount of signal, and that C18 
pipette tips, protease inhibitors, and freezing storage reduced neuropeptide concentrations in 
the tear film sample. 
The ELISA kits were typically designed to quantify analytes of interest in large-volume 
samples, such as blood, plasma/serum, tissues and cerebrospinal fluid with no less than 1 mL in 
volume. The kit protocol describes the procedure of extraction of peptides from the blood, 
plasma/serum, tissues and cerebrospinal fluid. However, when the same protocol was followed 
for the extraction of neuropeptides from tear samples, almost no peptides were detected. This 




used in future to test if neuropeptides can be quantified reliably from the tear film. Another 
method that can be used to test the influence of other proteins on the assay is to dilute the tear 
samples in BSA and in assay buffer and compare the concentration of neuropeptides between 
the preparations. Further experiments to be conducted can be to test the concentrations of 
CGRP, NPY and VIP between tears which were frozen, and freshly collected tears from the same 
participant.   
These experiments have provided some optimization steps to consider for tear sample 
collection and processing for the detection for neuropeptides. However, the highly variable 
results from the spike and recovery and serial dilution experiments suggest that further work is 









Chapter 5  – Evaluation of Substance P Neuropeptide ELISA Kits 
5.1  Introduction 
The Substance P (SP) neuropeptide ELISA kit from Phoenix Pharmaceuticals (Burlingame, CA, 
USA) has been used in previous studies evaluating the concentration of SP in the tear film.19,21,60 
This kit was used for measuring the concentration of SP in the tear film in Chapter 3, but the 
results of the troubleshooting experiments in Chapter 4 has raised some questions about its 
validity. This chapter builds on the previous data through continued investigations into the nature 
of the kit. In addition, the performance of another commercially available SP ELISA kit (Cayman 












5.1.1 Absorbance Spectrum  
Each chemical has a unique spectral absorbance profile and the absorbance profile may be 
helpful in determining the integrity of SP from various sources.77,78  
5.1.1.1 Purpose 
The purpose of this experiment was to test the similarity of the SP obtained from Phoenix 
Pharmaceuticals, Cayman Chemicals, and Sigma Aldrich.  
5.1.1.2 Method 
For this experiment, SP from Phoenix Pharmaceuticals (Burlingame, CA, USA), SP from Cayman 
Chemicals (Ann Arbor, Michigan, USA) and SP from Sigma-Aldrich (Oakville, ON, Canada) were 
each formulated at 0.5 mg/mL in 0.9% saline. Their UV absorbance profile from 200 nm to 300 
nm was obtained using SoftMax Pro 5.4.1 software on a SPECTRAmax M5e ROM v2.1.35 
(Molecular Devices, San Jose, CA 95134, USA). After each measurement, the cuvette was washed 





Fig 5-1 shows the similar absorbance profile of SP from Phoenix Pharmaceuticals and SP from 
Sigma Aldrich while, the absorbance profiles for SP from Cayman Chemicals is different than 
other two.  
 
Figure 5-1. Absorbance spectrum compared between the SP obtained from Phoenix    






5.2 Agreement between SP from Phoenix Pharmaceuticals and external SP in 
Phoenix Pharmaceuticals SP ELISA kit and Cayman Chemicals SP ELISA kit                                                                                                                                                                                                                                                                                               
Since the SP from Phoenix Pharmaceuticals and the SP from Sigma Aldrich have nearly identical 
spectral absorbance profiles, they could serve as two independent controls for eliciting the 
internal variability of the Phoenix Pharmaceuticals and Cayman Chemicals ELISA kits.  
5.2.1 Purpose  
The purpose of this experiment was to determine the quantity of known concentrations of two 
similar SP substances and determine their agreement with both the Phoenix Pharmaceuticals and 
Cayman Chemicals ELISA kit. 
5.2.2 Method  
5.2.2.1 SP ELISA kit from Phoenix Pharmaceuticals 
SP from Phoenix Pharmaceuticals and the SP from Sigma Aldrich were serially diluted to obtain 
concentrations of 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.2 pg/mL, 15.6 pg/mL, 7.8 
pg/mL, 3.9 pg/mL. The plate was pre-coated with the capture antibody. 50 μL of each of the 
prepared concentrations were added to each well in triplicates. 25 μL of the antibody-enzyme 




reagent was then removed by washing the plate three times with buffer and a substrate solution 
was added and incubated on an orbital shaker. After 20 minutes of incubation, the reaction was 
stopped and the fluorescence of each well was read at 325 nm for excitation and 420 nm for 
emission using SoftMax Pro 5.4.1 software on a SPECTRAmax M5e ROM v2.1.35 (Molecular 
Devices, San Jose, CA 95134, USA). Each concentration was plated in triplicate and the 
experiment was repeated three times.   
5.2.2.2 SP ELISA kit from Cayman Chemicals  
SP from Phoenix Pharmaceuticals and SP from Sigma Aldrich were serially diluted to obtain 
solutions with concentrations of 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.2 pg/mL, 
15.6 pg/mL, 7.8 pg/mL. 50 μL of each of the solutions were added to each well in triplicates, 
followed by 50 μL of SP AChE (acetylcholinesterase) tracer to each well. Then 50 μL of SP 
antiserum was added and the ELISA plate was incubated for 16 hours at 4°C. After 16 hours the 
content in the wells were discarded and the wells were washed five times with wash buffer 
provided with the kit. Ellman’s reagent (200 μL) was added to each plate and incubated for 2 
hours on an orbital shaker. After 2 hours of reaction, the absorbance intensity was determined 




Devices, San Jose, CA 95134, USA). Each concentration was plated in triplicate and the 
experiment was repeated three times. 
5.2.3 Statistical Analysis  
The results were analyzed using GraphPad Prism version 8.3.0. (San Diego, CA, USA). Bland-
Altman plots were used to determine the agreement of the SP from Phoenix Pharmaceuticals 
with the SP from Sigma Aldrich, for both the Phoenix Pharmaceuticals and Cayman Chemicals 
ELISA kit. Since the Phoenix Pharmaceuticals ELISA kit reported in fluorescence units and the 
Cayman Chemicals ELISA kit reported in absorbance units, the results were harmonized by 
reporting percentage difference against the average for the Bland Altman plots.  
5.2.4 Results  
Tables 5-1 and 5-2 describe the absorbance and fluorescence units (mean ± SD), and returned 
concentrations for each corresponding control concentration of SP from both Phoenix 







    Table 5-1 A summary of the absorbance units reported for each SP concentration measured 















500 pg/mL 0.289 ± 0.073 455.21 ± 108.15 0.313 ± 0.058 490.24 ± 96.67  
250 pg/mL 0.341 ± 0.081 218.15 ± 175.16 0.366 ± 0.070 334.54 ± 169.48 
125 pg/mL 0.396 ± 0.105 112.88 ± 73.47 0.432 ± 0.069 192.61 ± 71.41 
62.5 pg/mL 0.459 ± 0.105 80.90 ± 22.32 0.529 ± 0.100 52.42 ± 8.81 
31.2 pg/mL 0.559 ± 0.149 30.79 ± 13.46 0.607 ± 0.113 27.35 ± 17.01 
15.6 pg/mL 0.613 ± 0.175 38.74 ± 30.22 0.679 ± 0.126 10.31 ± 3.71 







    Table 5-2 A summary of the fluorescence units reported for each SP concentration measured 









Sigma Aldrich SP  




500 pg/mL 3055.881 ± 1259.030 593.12 ± 207.11 3223.587 ± 2525.388 413.64 ± 318.94 
250 pg/mL 4541.588 ± 2194.499 253.39 ± 80.08 4774.970 ± 3239.348 303.84 ± 218.99 
125 pg/mL 5836.092 ± 2812.233 113.64 ± 36.29 5857.764 ± 3758.113 134.09 ± 36.64 
62.5 pg/mL 6985.764 ± 3178.217 54.59 ± 23.96 6682.423 ± 3845.265 105.56 ± 55.34 
31.2 pg/mL 8023.917 ± 3272.647 27.53 ± 19.22 8257.590 ± 4924.259 26.25 ± 9.05 
15.6 pg/mL 8712.723 ± 3964.394 15.87 ± 5.92 9120.351 ± 4599.981 11.53 ± 3.58 
7.8 pg/mL 9107.385 ± 5236.212 14.09 ± 11.77 9707.319 ± 4346.209 6.69 ± 0.68 
3.9 pg/mL 9633.451 ± 4835.918 7.15 ± 3.23 10314.618 ± 
3989.103 





Fig 5-2 (a) and 5-2 (b) show the agreement between of SP from Phoenix Pharmaceuticals with 
the SP from Sigma Aldrich, for the Phoenix Pharmaceuticals ELISA kit and the Cayman Chemicals 
ELISA kit, respectively.  The mean difference was -3.36%, and the 95% limits of agreement were 
[-10.75, 4.01], for the Phoenix Pharmaceuticals kit. The mean difference for the Cayman Chemical 
kit was -9.70%, and the 95% limits of agreement were [-14.61, -4.79].  
 
Figure 5-2 (a) Bland-Altman Plot reporting the agreement between SP from Phoenix 
Pharmaceuticals and SP from Sigma Aldrich in the Phoenix Pharmaceuticals SP kit. The green line 
represents  the mean difference and the red dotted lines (above and below) represent the upper 





        Figure 5-2 (b) Bland-Altman Plot reporting the agreement between SP from Phoenix 
Pharmaceuticals and SP from Sigma Aldrich, using the Cayman Chemicals ELISA kit. The green line 
represents the mean difference and the red dotted lines (above and below) represent the upper 













5.3 Discussion and Conclusion  
The results from this chapter show that the Cayman Chemicals ELISA kit has a smaller 95% limits 
of agreement interval compared to the Phoenix Pharmaceuticals ELISA kit, despite a slightly 
higher mean difference. The detection of bias (mean difference) in both the kits suggests that 
overall, SP from both sources were not being quantified equally. This may be due to small 
differences with the chemicals that could affect the quantification from ELISA kits. Another 
reason for this difference may be due to the difference in the unit of quantification.  
The ELISA kit from Phoenix Pharmaceuticals measured SP in fluorescence units and the 
ELISA kit from Cayman Chemicals measured SP in absorbance units. Fluorescence is based on the 
emission of the light by a substance that was excited by a photon, while absorbance measures 
the amount of light absorbed by a substance at a given wavelength.79 While an assumption was 
made that the SP from Phoenix Pharmaceuticals and the SP from Sigma Aldrich were identical, 
they were not based on the spectral absorbance plots. This minor difference may explain the 
mean bias observed in the Bland Altman plots and overall poor agreement between the two SP 
substances.  
When examining the variability of the absorbance and fluorescence values corresponding 




ELISA kits (Tables 5-1 and 5-2) the variability in both absorbance and fluorescence increased 
towards lower control concentrations, while variability of the returned concentrations showed 
an opposite trend. This observation can be explained by the lower control concentrations 
returning concentrations which are likely outside the linear region of the standard curve. The 
high variability in fluorescence and absorbance units associated with low concentrations would 
also explain the poor agreement observed in the Bland Altman plots, in either kit. Since the 
working range of concentrations in this study was towards the lower end reported by some 
existing studies,17,18,20,22 future work to investigate a higher range of concentrations (e.g., greater 











Chapter 6– General Discussion  
The objective of this thesis was to develop and optimize a method for the quantification of 
neuropeptides (CGRP, SP, NPY, VIP) in the human tear film. While many of the studies in the 
literature only measured the concentration of SP and or CGRP 17,18,20-22,56 there are very few 
studies that have measured the concentration of all four neuropeptides in the tear film.19,60 The 
reported studies all have different approaches to tear film collection and neuropeptide 
quantification, which are likely the major reasons explaining the large variation observed in the 
reported quantities of these neuropeptides in the literature (summarized in Table 3-1). This large 
variability poses challenges in detecting meaningful changes in physiological levels. Thus, there 
is a need to determine methods of tear collection and optimize sample processing to reduce the 
sources of variability. The development and optimization steps of the neuropeptide ELISA are 
summarized in the following sections.  
The first objective of this study was to develop a method of tear collection and measure 
the concentration of neuropeptides (CGRP, SP, NPY, VIP) using a commercially available ELISA kit. 
The results from Chapter 3 showed that there was no significant difference in neuropeptide 
concentrations between basal and flush tear collection techniques, and no significant difference 




would yield a lower concentration than basal tears due to dilution, however, there was no 
significant difference detected between the two collection techniques. This finding raised 
fundamental questions about the validity of the ELISA technique for the quantification of 
neuropeptides in the tear film.  
The second objective of this study was to develop learnings (and test potential 
deficiencies) around the neuropeptide ELISA kits that had been used in previous studies. The 
results of the two tests (spike and recovery of neuropeptides and the response to dilution) 
suggested the possibility of tear film proteins interfering with the ELISA process. After conducting 
additional troubleshooting steps, it was concluded that a)  blocking agent did not improve assay 
results, b) albumin showed interference with the ELISA assay, c) neuropeptides were lost from 
using C18 column separation, d) neuropeptides were lost using protease inhibitors. Additionally, 
freshly collected tears yielded higher neuropeptide concentrations than tears stored at -80°C.  
The final aim of this study was to optimize an ELISA kit to measure the concentration of 
SP neuropeptide in the tear film. The variability two commercially available ELISA kits were 
measured and compared. The results from this experiment suggest that both SP ELISA kits from 




   Of note, there were several limitations to our clinical study population investigated 
using these kits, including participant recruitment, sample size and tear collection method. 
• Recruitment classification: The participants recruited for this study were included based 
solely on the OSDI questionnaire score to rule out symptoms of dry eye. This may have 
resulted in inclusion of participants with mild DED for this study, potentially influencing the 
amount of neuropeptides collected. Clinical tests to detect DED could have been used to fine-
tune the selection of participants. A more rigorous approach to selecting participants will be 
the focus for future work. 
• Sample size: We recruited only 10 participants and only 8 completed the study. Given the 
variation between basal and flush tears between day one and day two in individual 
participants, a larger sample size could have been used to detect smaller differences.  
• Tear collection method: This study used microcapillary glass tubes for collecting tears, which 
may have induced reflex tearing and diluted the concentrations of the neuropeptides 
collected from the tear film. This may be one of the reasons for failing to detect any significant 
difference between basal and flush tears.  
Future research efforts should be directed at continuing to optimize ELISA kits for 




could begin to explore the role of neuropeptides in various population groups, such as CL 
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